First Tracks Biotherapeutics enters the week of May 11 with a stark contradiction at its centre: six Wall Street firms initiated coverage in the past month with unanimous bullish ratings, yet the stock has shed 31% over the same period — a gap that defines the story heading into the June 1 earnings event.
The Street's opening salvo was emphatic. JP Morgan kicked off coverage on April 23 with Overweight and a $31 target. Barclays, Leerink Partners, UBS, HC Wainwright, and Piper Sandler all followed in rapid succession through early May, all landing at Overweight or Buy. Piper Sandler set the high-water mark at $54. The consensus mean target is now $39.43, implying more than 130% upside from Friday's close of $16.90. That gap is unusually wide even for a clinical-stage biotech. The bulls point to the Phase 1b data for ANB033 in celiac disease and eosinophilic esophagitis, cash runway through 2028, and leadership with prior sector experience. The bear case is harder to dismiss: no approved drugs, no revenue, trial endpoints subject to regulatory change, and pipeline depth that depends on continued AnaptysBio funding.
What drowned out the coverage blitz almost immediately was a resale prospectus filed on May 8, registering 10.5 million common shares for resale. That filing crystallised a supply overhang the market had already been pricing. It was preceded, notably, by a single large insider sale: EcoR1 Capital — a 10% owner with board representation — sold approximately 4.7 million shares on April 20 for roughly $65 million at $13.81 per share. That sale, representing the entirety of their reported recent activity, predated the coverage wave and flagged early that a significant holder was reducing exposure into anticipated institutional attention. The stock has not recovered. It closed Friday at $16.90, down nearly 7% on the day and 13.5% on the week.
Positioning in the lending market tells a quieter story. Availability is loose — borrow demand remains well below the stress levels seen in late April, when utilisation briefly spiked to a 52-week high of 66.8% before collapsing to its current 16.2%. Cost to borrow has also eased from a peak above 0.87% on April 21 to roughly 0.42% now, running near the bottom of its recent range. Short interest has barely moved, ticking up just 0.5% in the latest daily estimate to around 4.3 million shares. Without float data it's difficult to calculate the precise percentage, but the FINRA fortnightly figure of 4.03 million shares and 7.5 days-to-cover suggests shorts are patient rather than pressing. Options positioning is skewed heavily toward calls — the put/call ratio of 0.19 is far below the 52-week high of 0.32, meaning the options market is not positioned for continued selling; there is little hedging activity relative to the recent history.
The most recent earnings event, announced May 14, saw the stock fall 8.3% the following day. With the next print scheduled for June 1, that reaction will be in focus. Institutional ownership remains thin — the top holder is EcoR1 at 9.1%, but given their April sale, that position has likely been reduced. BlackRock and State Street hold small index-linked positions below 2%. The base remains concentrated and lightly covered, which amplifies both the impact of news flow and the distance between the sell-side consensus and where the stock actually trades.
The convergence of a resale overhang, a significant insider exit, and a stock trading at roughly 43 cents on the Street's average dollar of implied value means the June 1 earnings event carries unusual weight — the question is whether the ANB033 trial data can begin to close that gap, or whether supply continues to set the terms.
See the live data behind this article on ORTEX.
Open TRAX on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
